Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Gisoo Zarrabi

Psychiatry Costa Mesa, CA Medical Doctor

NPI 1760707152 CMS profile 755499

275 Victoria St, Costa Mesa, CA 92627

Open in the dashboard

General payments

$10,575

614 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Gisoo Zarrabi of Costa Mesa, CA is reported in the CMS Open Payments database as having received $10,575 across 614 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $18 1
2023 General $43 2
2022 General $1,252 58
2021 General $3,225 170
2020 General $2,528 145
2019 General $3,508 238

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gisoo Zarrabi
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Gisoo Zarrabi were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Gisoo Zarrabi Psychiatry median Middle half National median
2019 $3,508 $184 $59–$605 $163
2020 $2,528 $119 $36–$372 $114
2021 $3,225 $143 $43–$576 $132
2022 $1,252 $153 $50–$590 $149
2023 $43 $170 $56–$651 $160
2024 $18 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Sunovion Pharmaceuticals Inc. $1,787 71 payments
  2. Janssen Pharmaceuticals, Inc $1,360 51 payments
  3. Allergan Inc. $1,139 70 payments
  4. AbbVie, Inc. $973 55 payments
  5. Otsuka America Pharmaceutical, Inc. $953 82 payments
  6. Neurocrine Biosciences, Inc. $646 58 payments
  7. Teva Pharmaceuticals USA, Inc. $591 66 payments
  8. ITI, Inc. $502 23 payments
  9. Alkermes, Inc. $496 27 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $391 20 payments
  11. Other $1,737 91 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $10,517 612 payments
  2. Education $58 2 payments
Products named General payments · program years 2019–2024
  1. LATUDA $1,787 71 payments
  2. SPRAVATO $1,306 49 payments
  3. VRAYLAR Neuroscience $1,127 68 payments
  4. VRAYLAR Neuroscience $827 49 payments
  5. REXULTI $627 56 payments
  6. AUSTEDO $591 66 payments
  7. INVEGA SUSTENNA $508 29 payments
  8. CAPLYTA $502 23 payments
  9. INVEGA TRINZA $499 27 payments
  10. INGREZZA $417 42 payments
  11. Other $5,519 301 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

614 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record